Literature DB >> 16586089

Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Han-Ting Zhang1, Yu Zhao, Ying Huang, Chengjun Deng, Allen T Hopper, Michael De Vivo, Gregory M Rose, James M O'Donnell.   

Abstract

RATIONALE: Phosphodiesterase-4 (PDE4) has two conformation states based on rolipram binding, the high-affinity rolipram binding state (HARBS) and the low-affinity rolipram binding state (LARBS); their functions remain to be fully explained.
OBJECTIVE: Experiments were carried out to determine the roles of the HARBS and LARBS in the mediation of antidepressant-like effects on behavior.
MATERIALS AND METHODS: Two animal models sensitive to antidepressant drugs, the forced-swim test (FST), and the differential-reinforcement-of-low-rate (DRL) 72-s operant schedule, were used to examine the antidepressant-like effects of rolipram, CDP840, and piclamilast, PDE4 inhibitors that interact differentially with the HARBS and LARBS, and MEM1018 and MEM1091, two novel PDE4 inhibitors. Drug discrimination vs rolipram and rolipram competition binding assays also were carried out.
RESULTS: In the FST, rolipram and piclamilast, both at 0.1 mg/kg, produced an antidepressant-like effect, i.e., reduced immobility and increased swimming, whereas, 1 mg/kg of CDP840 or 0.5 mg/kg of MEM1018 or MEM1091 was required to produce a similar effect. Consistent with this, only rolipram and piclamilast produced antidepressant-like effects in rats under the DRL schedule of reinforcement, as evidenced by decreased response rates and increased reinforcement rates. In addition, in rats trained to discriminate rolipram from its vehicle, only rolipram and piclamilast substituted. Finally, [(3)H]rolipram and [(3)H]piclamilast binding analysis revealed that CDP840 and the two novel PDE4 inhibitors MEM1018 and MEM1091 exhibited a lower affinity for the HARBS than did rolipram.
CONCLUSION: These results suggest that the HARBS of PDE4 is the primary conformation important for antidepressant-like effects on behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586089     DOI: 10.1007/s00213-006-0369-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

3.  Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.

Authors:  R Schmiechen; H H Schneider; H Wachtel
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor.

Authors:  M Asanuma; S Nishibayashi; E Iwata; Y Kondo; T Nakanishi; M G Vargas; N Ogawa
Journal:  Brain Res Mol Brain Res       Date:  1996-09-05

5.  Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.

Authors:  J M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

6.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

7.  Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.

Authors:  H T Zhang; A M Crissman; N R Dorairaj; L J Chandler; J M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2000-08       Impact factor: 7.853

8.  Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats.

Authors:  Han-Ting Zhang; Ying Huang; Neesha U Suvarna; Chengjun Deng; Alicia M Crissman; Allen T Hopper; Michael De Vivo; Gregory M Rose; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

9.  Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.

Authors:  A J Duplantier; M S Biggers; R J Chambers; J B Cheng; K Cooper; D B Damon; J F Eggler; K G Kraus; A Marfat; H Masamune; J S Pillar; J T Shirley; J P Umland; J W Watson
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

10.  [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants].

Authors:  K Nakamura; Y Ikoma; K Kimura; Y Nakada; S Kobayashi; M Yamaguchi; H Nakagawa
Journal:  Nihon Yakurigaku Zasshi       Date:  1989-07
View more
  23 in total

Review 1.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

2.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

3.  Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Authors:  Lan Xiao; James P O'Callaghan; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

4.  Intra-nucleus accumbens shell injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice.

Authors:  Chelsea R Kasten; Stephen L Boehm
Journal:  Behav Brain Res       Date:  2014-07-12       Impact factor: 3.332

5.  Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.

Authors:  Tatiana V Lipina; Oksana Kaidanovich-Beilin; Satish Patel; Min Wang; Steven J Clapcote; Fang Liu; James R Woodgett; John C Roder
Journal:  Synapse       Date:  2011-03       Impact factor: 2.562

Review 6.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

7.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

8.  PET measurement of the in vivo affinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats.

Authors:  Tetsuji Itoh; Kohji Abe; Sami S Zoghbi; Osamu Inoue; Jinsoo Hong; Masao Imaizumi; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

9.  Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.

Authors:  Zaorui Zhao; Alicia M Baros; Han-Ting Zhang; M Danet S Lapiz; Corina O Bondi; David A Morilak; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-04-16       Impact factor: 7.853

10.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.

Authors:  Yun-Feng Li; Ying Huang; Simon L Amsdell; Lan Xiao; James M O'Donnell; Han-Ting Zhang
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.